Key facts
- Outpace Bio’s last known valuation is $220.0M.
- It has raised $199.0M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($144.0M) in Jul 2024.
- Notable investors include Mana Ventures, Gaingels, RA Capital Management, Abstract Ventures, Qiming Venture Partners — 20 tracked in total.
- Outpace Bio has filed 1 Form D with the SEC, most recently Aug 2024 ($56.0M sold to 25 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Outpace Bio
Funding rounds
1 roundsAbout Outpace Bio
Developer of cell therapies designed to improve the safety and efficacy of gene therapies. The company's versatile platform combines the design of biological functions with cellular control modalities, harnessing the complexity of cellular biology to tackle incurable diseases, it uses AI powered protein design to deliver cell therapy for solid tumors by programming cells for improved function inside the patient, enabling companies to collaborate with industry leaders by incorporating insights and creating therapies using protein design and synthetic biology.
- Industry
- Discovery Tools (Healthcare)
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2020
- Employees
- 71
- Website
- outpacebio.com/
- Ownership
- Privately Held (backing)
Outpace Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Outpace Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Outpace Bio in its N-PORT filings yet. We sweep new filings monthly.